A Study of Risk Enabled Therapy After Neoadjuvant Immunochemotherapy for Bladder Cancer

Condition:   Muscle-Invasive Bladder Carcinoma Intervention:   Drug: AMVAC + Nivolumab Sponsor:   Fox Chase Cancer Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials